<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Evolus Inc — News on 6ix</title>
<link>https://6ix.com/company/evolus-inc</link>
<description>Latest news and press releases for Evolus Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 14 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/evolus-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835639778dffbe2df0ef502.webp</url>
<title>Evolus Inc</title>
<link>https://6ix.com/company/evolus-inc</link>
</image>
<item>
<title>Evolus to Report First Quarter Financial Results on May 4, 2026</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-to-report-first-quarter-financial-results-on-may-4-2026</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-to-report-first-quarter-financial-results-on-may-4-2026</guid>
<pubDate>Tue, 14 Apr 2026 12:30:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., April 14, 2026--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial results on Monday, May 4, 2026, after the U.S. financial markets close.</description>
</item>
<item>
<title>Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-to-participate-in-the-needham-25th-annual-virtual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-to-participate-in-the-needham-25th-annual-virtual-healthcare-conference</guid>
<pubDate>Tue, 31 Mar 2026 12:00:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., March 31, 2026--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Virtual Healthcare Conference.</description>
</item>
<item>
<title>Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-reports-fourth-quarter-and-full-year-2025-financial-results-delivers-sixth-consecutive-year-of-double-digit-growth-and-expects-sustainable-profitability1-beginning-in-2026</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-reports-fourth-quarter-and-full-year-2025-financial-results-delivers-sixth-consecutive-year-of-double-digit-growth-and-expects-sustainable-profitability1-beginning-in-2026</guid>
<pubDate>Tue, 03 Mar 2026 21:05:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., March 03, 2026--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the fourth quarter and full-year ended December 31, 2025.</description>
</item>
<item>
<title>Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability¹ Beginning in 2026</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-reports-fourth-quarter-and-full-year-2025-financial-results-delivers-sixth-consecutive-year-of-double-digit-growth-and-expects-sustainable-profitability-beginning-in-2026-88</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-reports-fourth-quarter-and-full-year-2025-financial-results-delivers-sixth-consecutive-year-of-double-digit-growth-and-expects-sustainable-profitability-beginning-in-2026-88</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>Total Net Revenue of $90.3 Million for the Fourth Quarter and $297.2 Million for the Full-Year 2025, Representing Growth of 14% and 12% Over the Prior Year</description>
</item>
<item>
<title>Evolus to Participate in The Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-to-participate-in-the-leerink-partners-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-to-participate-in-the-leerink-partners-global-healthcare-conference</guid>
<pubDate>Wed, 25 Feb 2026 13:00:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., February 25, 2026--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Leerink Partners Global Healthcare Conference in Miami, FL.</description>
</item>
<item>
<title>Evolus to Report Fourth Quarter and Full-Year 2025 Financial Results on March 3, 2026</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-report-fourth-quarter-full-130000329</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-report-fourth-quarter-full-130000329</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., February 17, 2026--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and full-year 2025 financial results on Tuesday, March 3, 2026, after the U.S. financial markets close.</description>
</item>
<item>
<title>Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-reports-inducement-grants-under-210500644</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-reports-inducement-grants-under-210500644</guid>
<pubDate>Fri, 13 Feb 2026 21:05:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., February 13, 2026--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today reported the grant during December 2025, January 2026, and February 2026 of an aggregate of 153,218 restricted stock units (RSUs) and 34,952 stock options of the company’s common stock to 36 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of directors unde</description>
</item>
<item>
<title>Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Net Revenue</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-announces-preliminary-unaudited-fourth-133000108</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-announces-preliminary-unaudited-fourth-133000108</guid>
<pubDate>Fri, 09 Jan 2026 13:30:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., January 09, 2026--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2025. The preliminary unaudited results described in this press release are based on the most current information available to management and are subject to change until the audit of the company’s 2025 financial results is completed a</description>
</item>
<item>
<title>Evolus Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-reports-third-quarter-2025-210500124</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-reports-third-quarter-2025-210500124</guid>
<pubDate>Wed, 05 Nov 2025 21:05:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., November 05, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Evolus to Participate in 2025 Stifel Healthcare Conference</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-participate-2025-stifel-healthcare-120000160</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-participate-2025-stifel-healthcare-120000160</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., October 28, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its management team will participate in a fireside chat and investor meetings at the upcoming Stifel Healthcare Conference.</description>
</item>
<item>
<title>Evolus to Report Third Quarter Financial Results on November 5, 2025</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-report-third-quarter-financial-120000100</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-report-third-quarter-financial-120000100</guid>
<pubDate>Wed, 22 Oct 2025 12:00:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., October 22, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025, after the U.S. financial markets close.</description>
</item>
<item>
<title>Top Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse™ Filler Launch</title>
<link>https://6ix.com/company/evolus-inc/news/top-miami-plastic-surgeon-dr-benjamin-eskenazi-named-lead-consultant-for-evolus-evolyssetm-filler-launch</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/top-miami-plastic-surgeon-dr-benjamin-eskenazi-named-lead-consultant-for-evolus-evolyssetm-filler-launch</guid>
<pubDate>Mon, 22 Sep 2025 13:03:00 GMT</pubDate>
<description>Evolus, Inc. (NASDAQ: EOLS), a leading publicly traded aesthetic beauty company, has named Dr. Benjamin Eskenazi, MD, FACS, founder of Miami Beach's premier Avabello Aesthetics, as lead consultant for the national launch of their revolutionary Evolysse™ filler line. This partnership comes as Evolus introduces the first major technological breakthrough in hyaluronic acid dermal fillers in a decade, with Dr. Eskenazi providing critical expertise to support aesthetic providers nationwide.</description>
</item>
<item>
<title>Evolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-announces-inducement-grants-under-213000237</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-announces-inducement-grants-under-213000237</guid>
<pubDate>Fri, 12 Sep 2025 21:30:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., September 12, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 8,744 shares of Evolus common stock and an aggregate of 15,000 restricted stock units (RSUs) of the company’s common stock to 6 newly hired non-executive employees of the company, and 143,403 shares of Evolus common stock and 104,603 RSUs of the c</description>
</item>
<item>
<title>Evolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-announces-appointment-tatjana-mitchell-123000934</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-announces-appointment-tatjana-mitchell-123000934</guid>
<pubDate>Mon, 08 Sep 2025 12:30:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., September 08, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Tatjana Mitchell as its Chief Financial Officer, effective September 8, 2025.</description>
</item>
<item>
<title>Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-announces-positive-data-pivotal-120000484</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-announces-positive-data-pivotal-120000484</guid>
<pubDate>Mon, 25 Aug 2025 12:00:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., August 25, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.</description>
</item>
<item>
<title>Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-announces-submission-premarket-approval-120000075</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-announces-submission-premarket-approval-120000075</guid>
<pubDate>Wed, 20 Aug 2025 12:00:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., August 20, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.</description>
</item>
<item>
<title>Evolus Reports Second Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-reports-second-quarter-2025-200500294</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-reports-second-quarter-2025-200500294</guid>
<pubDate>Tue, 05 Aug 2025 20:05:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., August 05, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the second quarter ended June 30, 2025.</description>
</item>
<item>
<title>Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading Neurotoxins</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-announces-publication-independent-study-120500405</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-announces-publication-independent-study-120500405</guid>
<pubDate>Thu, 31 Jul 2025 12:05:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., July 31, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of a landmark independent study in JAMA Dermatology directly comparing four leading botulinum toxin type A products for the treatment of glabellar lines: Jeuveau® (prabotulinumtoxinA-xvfs), Botox® (onabotulinumtoxinA), Dysport® (abobotulinumtoxinA), and Xeomin® (incobotulinumtoxinA).</description>
</item>
<item>
<title>Evolus to Report Second Quarter Financial Results on August 5, 2025</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-report-second-quarter-financial-120500607</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-report-second-quarter-financial-120500607</guid>
<pubDate>Tue, 22 Jul 2025 12:05:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., July 22, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the U.S. financial markets close.</description>
</item>
<item>
<title>Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France</title>
<link>https://6ix.com/company/evolus-inc/news/evolus-expands-global-footprint-introduction-120000653</link>
<guid isPermaLink="true">https://6ix.com/company/evolus-inc/news/evolus-expands-global-footprint-introduction-120000653</guid>
<pubDate>Wed, 09 Jul 2025 12:00:00 GMT</pubDate>
<description>NEWPORT BEACH, Calif., July 09, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has partnered with Symatese to commence distribution of Nuceiva® (botulinum toxin type A) in France.</description>
</item>
</channel>
</rss>